KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) and Eisai oCo. Ltd (ESALY.PK) on Tuesday said that the Phase 3 LITESPARK-011 trial evaluating Merck's WELIREG in combination with Eisai's LENVIMA met one of its primary endpoints of progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after treatment with anti-PD-1/L1 therapy.
The combination demonstrated a statistically significant and clinically meaningful improvement in PFS compared with cabozantinib at an interim analysis. Overall survival (OS), the study's other primary endpoint, will be evaluated at a future analysis.
Merck and Eisai said the safety profiles of WELIREG and LENVIMA were consistent with previous studies of the individual therapies, and no new safety signals were observed.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
